Human Milk and Its Effect on Infant's Metabolism and Infant Gut Microbiome (MAINHEALTH)

May 9, 2023 updated by: University of Aarhus

The Influence of Maternal Health on Human Breast Milk Composition With Potential Downstream Effects on Infant Metabolism and Gut Colonization

This protocol explains the MAINHEALTH cohort. The study examine the influence of maternal health parameters on human breast milk composition and integrates milk phenotype with infant metabolism and infant gut microbial content and metabolism.

Study Overview

Detailed Description

The birth of a living human being is the result of an approximately nine-month pregnancy in which the developing foetus has taken exactly the building blocks necessary to grow and develop from its mother. However, growth and development continues in multiple dimensions at an increasing pace after birth. The nutrition in the first 1,000 days from conception to the child's 2nd birthday plays a pivotal role in shaping the future health of the child. Yet, little is known of how breast milk components vary due to maternal factors or of the biological mechanisms behind the beneficial actions of many breast milk nutrients. The investigators propose to overcome these obstacles by combining specialties to give a more complete account of what breast milk is (major and minor milk constituents and microbiota), how it affects the infants directly or indirectly through breast milk-gut microbiome interactions and by which mechanisms. In this study longitudinal samples from 200 mother-infant dyads during the first year of life across three groups of pregestational maternal BMI; normal weight (BMI 18.5-24.99), overweight (BMI 25-30), and obese (BMI >30) are collected. The samples give a comprehensive record of what the infant has ingested (milk samples) and how the infant and infant gut microbiome responds to this (infant urine and feces). Maternal diet in pregnancy and at milk sample deliveries are recorded through a 24h online food recall and diary system. Maternal health attributes will, besides BMI, be analysed through clinical blood biochemistry parameters. Follow-up samples and infant dietary intake as the infant grows allow investigating how early life diet shaped infant growth and gut colonization more long term. The investigators have formed an experienced team of scientists within metabolomics, microbiology and medicine, holding leading positions within their respective fields in Denmark. The novelty in the study is the interdisciplinarity, unique study design and the emphasis to integrate a number of dynamic measurements thereby offering the ability to identify the factors in breast milk affecting infant metabolism and gut colonization. Knowing this enable the optimization of infant formula.

The research questions asked in this project are three-fold.

  • First, the investigators want to determine the variability of breast milk nutrients by application of multi-omics (metabolomics, proteomics and glycomics). The production of human breast milk has a high maternal metabolic cost. Thus, hypothesis is that maternal health attributes (metabolic dysfunction or obesity) influence which breast milk nutrients are made available to the infant.
  • Second, the investigators want to establish the microbiome of breast milk. Maternal obesity can lead to an apparent gut microbial ecology and increases the risk of obesity for the child. Thus, the hypothesis is that maternal obesity confers distinct microorganisms to the infant.
  • Third, the investigators want to identify biological mechanisms for how breast milk nutrients are metabolised in the infants. Infants exclusively breast-feeding offer total compliance. Thus, the hypothesis is that by deconstructing breast milk components and markers of infant metabolism through comprehensive analysis of infant urine and feces, bioactivity of breast milk nutrients can be elucidated.

Study Type

Observational

Enrollment (Actual)

168

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Aarhus, Denmark, 8200
        • Aarhus University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Residence in Aarhus area is necessary and Aarhus University Hospital has to be the place of giving birth. This is due to samples being collected by midwifes during labor and when study personnel collect samples in study participants' homes.

Description

Inclusion Criteria related to mother:

  • Residing in Aarhus area
  • Above 18 years of age
  • BMI above 18.5 kg/m2
  • Intention to breastfeed the first four to six months following birth
  • Be able to communicate in Danish

Exclusion Criteria related to mother:

  • Smoking
  • Multiple gestation
  • Suffering from the following chronic diseases that demands medical treatment: diabetes mellitus, celiac disease, inflammatory bowel disease (Chrohn's disease or ulcerosa colitis)
  • Taking medicaments for irritable bowel syndrome
  • Taking medicine for metabolic disorders
  • Taking medicine for psychological disorders
  • Have had gastric bypass surgery
  • Planned caesarean section
  • Received antibiotics after week 12 in their pregnancy
  • Utilizing significant amount of infant formula following birth

Inclusion Criteria related to infant:

  • Infants born after gestational age 37 weeks
  • Infants with a birth weight between 2500 g and 5000 g

Exclusion Criteria related to infant:

• Inborn errors of metabolism

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Maternal pre-gestational BMI 18.5<25
Maternal pre-gestational BMI 25<30
Maternal pre-gestational BMI >30

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Metabolite profile of human milk
Time Frame: Birth to 3 months
Human milk metabolites by Nuclear Magnetic Resonance (NMR) spectroscopy. Data will be analysed as absolute concentrations of milk metabolites; how milk metabolite profiles are related to mother's blood chemistry, milk microbial profiles, milk oligosaccharides, infant urine metabolome, and infant fecal microbiomes will be explored using multivariate analyses.
Birth to 3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Metabolite profile of human milk by Liquid Chromatography-Mass Spectrometry (LC-MS) analysis
Time Frame: Birth to 3 months
Human milk metabolites by LC-MS-based metabolomics. Data will be analysed as absolute concentrations of milk metabolites; how milk metabolite profiles are related to milk microbial profiles, milk oligosaccharides, infant urine metabolome, and infant fecal microbiomes will be explored using multivariate analyses.
Birth to 3 months
Milk proteome profile
Time Frame: Birth to 3 months
Human milk proteome by LC-MS-based, bottom-up proteomics. Data will be analysed as relative abundances of milk proteins.
Birth to 3 months
Milk protein post-translational modification (PTM) profile
Time Frame: Birth to 3 months
Post-translational modifications of human milk proteins is analysed by LC-MS-based and 2D- gel-based proteomics. Data will be analysed as relative abundances of milk protein PTMs.
Birth to 3 months
Milk glycome profile
Time Frame: Birth to 3 months
Human milk glycome by LC-MS-based glycomics. Data will be analysed as relative abundances of milk glycans.
Birth to 3 months
Microbial structure of human milk
Time Frame: Birth to 3 months
Human milk microbiome by nanopore sequencing. Data will be analysed as relative abundances of bacteria from phylum to genus levels.
Birth to 3 months
Microbial structure of infant feces
Time Frame: Birth to 5 years of age
Infant fecal microbiome by nanopore sequencing. Data will be analysed as relative abundances of bacteria from phylum to genus levels.
Birth to 5 years of age
Microbial structure of infant oral cavity
Time Frame: 30 days postpartum
Oral cavity microbiome by nanopore sequencing. Data will be analysed as relative abundances of bacteria from phylum to genus levels.
30 days postpartum
Microbial structure of mother's skin microbiome
Time Frame: 30 days postpartum
Skin microbiome by nanopore sequencing. Data will be analysed as relative abundances of bacteria from phylum to genus levels.
30 days postpartum
Metabolite profile of infant fecal material
Time Frame: Birth to 5 years of age
Infant fecal metabolome by NMR-based metabolomics. Data will be analysed as absolute concentrations of fecal metabolites
Birth to 5 years of age
Infant metabolism investigated by infant urine metabolomics
Time Frame: Birth to 3 months of age
Infant urine metabolome by NMR-based metabolomics. Data will be analysed as absolute concentrations of urine metabolites
Birth to 3 months of age
Microbial structure of maternal vagina and rectum to investigate vertical transmission of bacteria to infant during birth
Time Frame: During birth
Vertical transmission of microbiome from mother to infant. Vaginal and rectal microbiome by nanopore sequencing. Data will be analysed as relative abundances of bacteria from phylum to genus levels.
During birth
Mother's 24-h dietary recall (myfood24)
Time Frame: During pregnancy (Gestational age 30), 30, 60, and 90 days postpartum. In each case two times within a week (one weekday and one weekend day).
Aggregated nutrient intake data (e.g. proteins, vitamins, fibers, omega-3-fatty acids)
During pregnancy (Gestational age 30), 30, 60, and 90 days postpartum. In each case two times within a week (one weekday and one weekend day).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ulrik K Sundekilde, PhD, University of Aarhus

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2019

Primary Completion (Anticipated)

February 28, 2027

Study Completion (Anticipated)

April 30, 2028

Study Registration Dates

First Submitted

September 24, 2021

First Submitted That Met QC Criteria

October 27, 2021

First Posted (Actual)

November 8, 2021

Study Record Updates

Last Update Posted (Estimate)

May 11, 2023

Last Update Submitted That Met QC Criteria

May 9, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 1-10-72-296-18

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Milk Collection

3
Subscribe